Edmond DE Rothschild Holding S.A. Has $300,000 Stake in Becton Dickinson and Co (BDX)

Edmond DE Rothschild Holding S.A. decreased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 30.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,330 shares of the medical instruments supplier’s stock after selling 592 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Becton Dickinson and were worth $300,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after acquiring an additional 283,433 shares during the period. Vanguard Group Inc grew its stake in Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after acquiring an additional 283,433 shares during the period. BlackRock Inc. grew its stake in Becton Dickinson and by 1.9% in the 4th quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after acquiring an additional 355,223 shares during the period. FMR LLC grew its stake in Becton Dickinson and by 8.0% in the 3rd quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock valued at $4,529,401,000 after acquiring an additional 1,286,579 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its stake in Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 6,545,502 shares during the period. 85.46% of the stock is currently owned by institutional investors and hedge funds.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the transaction, the chief executive officer now owns 227,250 shares in the company, valued at approximately $56,903,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ribo Alberto Mas sold 4,808 shares of Becton Dickinson and stock in a transaction on Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $1,226,184.24. Following the transaction, the executive vice president now owns 22,476 shares in the company, valued at approximately $5,732,054.28. The disclosure for this sale can be found here. Insiders sold a total of 19,271 shares of company stock worth $4,862,179 in the last 90 days. 0.12% of the stock is currently owned by insiders.

Shares of BDX stock opened at $253.92 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. The firm has a market capitalization of $68.32 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 1.76 and a beta of 1.21. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.58 by $0.12. The company had revenue of $4.16 billion for the quarter, compared to analyst estimates of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.48 EPS. Sell-side analysts expect that Becton Dickinson and Co will post 12.1 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be issued a $0.77 dividend. The ex-dividend date is Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a yield of 1.21%. Becton Dickinson and’s payout ratio is currently 27.97%.

A number of research firms recently issued reports on BDX. TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Zacks Investment Research cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. Piper Jaffray Companies lifted their price target on shares of Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research note on Tuesday, February 5th. Morgan Stanley dropped their price target on shares of Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Finally, Citigroup dropped their price target on shares of Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating on the stock in a research note on Wednesday, January 2nd. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $253.55.

TRADEMARK VIOLATION NOTICE: This story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2019/03/17/edmond-de-rothschild-holding-s-a-has-300000-stake-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Index Funds

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.